Writing
Analysis and essays on how breakthroughs in science and technology reshape industries, economies, and power.
Personal essays
Molecules & Empires
Where I step back from the industry beat and look at the forces actually reshaping how science, technology, and money interact. Where AI stops being a tool and starts being an actor. Where a single class of drugs rewrites the economics of healthcare overnight. A notebook on how breakthroughs create winners and losers at every scale — from startups to superpowers.
-
Can a Biohacker With AI Tools Do Pharma's Job?
The hype around a tech entrepreneur, his dying dog, and a cancer vaccine he designed using AI tools gets almost everything wrong. The thing it gets right will one day reshape medicine.Mar 2026 -
Gatekeepers of the New Baseline
GLP-1 drugs, longevity, and the real cost of controlling human metabolismFeb 2026 -
A Thought About Aging I Can’t Unsee
We are not one organism.Dec 2025
Industry intelligence · Published by BiopharmaTrend
Where Tech Meets Bio
Deep dives into AI drug discovery, computational biology, and the competitive dynamics reshaping pharma R&D. Co-authored with Roman Kasianov and published through BiopharmaTrend — the industry intelligence platform I co-founded in 2016.
-
Simulating the Control Arm: Virtual Patients at the Trial Bottleneck
Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.Mar 14, 2026 -
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.Mar 7, 2026 -
Cancer as a Data Problem: What AI Is Doing in Oncology
We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to handle multi-step oncology research tasks.Feb 27, 2026